Assessment Status |
Assessment process complete |
HTA ID |
- |
Drug |
Ledipasvir/sofosbuvir |
Brand |
Harvoni® |
Indication |
For the treatment of Chronic Hepatitis C (CHC) infection (Genotye 1, 3 and 4) in adults. |
Rapid review commissioned |
14/11/2014 |
Rapid review completed |
18/12/2014 |
Rapid review outcome |
Full Pharmacoeconomic Assessment Recommended |
Full pharmacoeconomic assessment commissioned by HSE |
18/03/2015 |
NCPE assessment completed |
20/11/2015 |
NCPE assessment outcome |
Reimbursement Recommended for Genotype 1 and 4. |